1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Earnings

Reaching 'Transformation' In Turnaround Phase 1, Perrigo Looks To Build On Its Accomplishments

 
• By Malcolm Spicer

Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.

Perrigo provides data on separate periods to show a return to net sales growth with adjusted operating income stabilized as it invested to modernize, partially by restoring its historical growth formula • Source: Perrigo

Perrigo Company PLC is turning the page on its makeover strategy, moving from transforming its portfolio and operations to optimizing its businesses while accelerating growth.

As the consumer health products private label leader touts its path ahead, shareholders likely are noting it ended each of the past two years with the same full-year net loss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

BioGaia Takes Probiotics To Netherlands For First Time

 
• By Tom Gallen

Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By David Ridley

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Dermapharm Seeks To Put Stop To Spanish Slide

 
• By Tom Gallen

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

More from Business